The FDA’s Purple Book is supposed to be the authoritative public registry for biologic drug patents in the United States.
Biologic Patent Tracking: What to Do When the Purple Book Fails You Read Post »
How combination patent architecture protects pharmaceutical revenue after composition-of-matter expiry — and what the post-Teva v. Amneal landscape means for
Your Drug Needs a Device Patent to Survive: The MedTech Crossover Strategy Read Post »
When a small-molecule drug loses its composition-of-matter patent, the conventional story is that the clock runs out and generic manufacturers
Platform Technology Patents: The IP Moat That Outlasts Any Single Molecule Read Post »
Two protection systems govern pharmaceutical market exclusivity in the United States. One is a private intellectual property right, contested in
Orphan Drug Exclusivity vs. Patent: Who Wins the Market War Read Post »
Most pharmaceutical companies treat patent disclosures as a legal obligation. The better ones treat them as a revenue forecast. The
Patent Intelligence That Wins Investors: How Pharma Companies Prove IP Defensibility Read Post »
The short answer is: yes, you can use PAT-INFORMED to find drug patent information, including grant dates and expiry dates
PAT-INFORMED for Drug Patent LOE Dates: What It Can (and Cannot) Tell You Read Post »
For most of the 20th century, pharmaceutical intellectual property was a single-act play. You discovered a molecule, filed a composition-of-matter
The Platform Technology Moat: Why the Single-Molecule Patent No Longer Wins the IP War Read Post »
Every year, billions of dollars in generic-entry forecasts are built on a single assumption: that the patent expiry date listed
Patent Term Extensions: The Most Misunderstood Dates in Pharma Read Post »
The moment a generic competitor files an Abbreviated New Drug Application, the brand manufacturer’s revenue clock starts ticking. But the
Sign in or create a free account to read this DrugPatentWatch article
